<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605056</url>
  </required_header>
  <id_info>
    <org_study_id>SHZS-MM001</org_study_id>
    <nct_id>NCT03605056</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM</brief_title>
  <official_title>Chindamide in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma, a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peng Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chipscreen Biosciences, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of combination of
      Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All the patients involved in this study will receive a 3-drug regimen (chindamide, lenalidomide and dexamethasone)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>according to IMWG criteria, including the rate of complete remission (CR), very good partial remission (VGPR) and partial remission (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of people in the study group who are still alive 2 years after the start of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CRD regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chidamide</intervention_name>
    <description>20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle</description>
    <arm_group_label>CRD regimen</arm_group_label>
    <other_name>Epidaza</other_name>
    <other_name>CS055</other_name>
    <other_name>HBI-8000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>25 mg/d, will be administered orally on Days 1-14 each 21 day cycle</description>
    <arm_group_label>CRD regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>40mg weekly, will be administered orally or intravenously</description>
    <arm_group_label>CRD regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient ≥ age 18 years

          -  Patient is able to understand and has given voluntary written informed consent before
             performance of any study-related procedures not part of normal medical care, with the
             understanding that consent may be withdrawn by the patient at any time without
             prejudice to their future medical care

          -  Patient has been previously diagnosed with MM based on standard International Myeloma
             Working Group (IMWG) criteria and currently requires treatment.

          -  Patient must have received at least one previous line of therapy for multiple myeloma
             including bortezomib

          -  Patient must have demonstrated disease progression on or within 60 days of completion
             of the last therapy. Patient has measurable disease defined as at least one of the
             following:

          -  Serum M protein ≥ 0.5 g/dL (≥5 g/L)

          -  Urine M protein ≥200 mg/24 hours

          -  Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an
             abnormal serum FLC ratio (&lt;0.26 or &gt;1.65)

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Negative serum or urine pregnancy test for women of child-bearing potential

          -  Screening Laboratory parameters:

          -  Absolute neutrophil count (ANC) ≥ 1,500 cells/dL (1.5 x 10^9/L). Granulocyte
             colony-stimulating factor (GCSF) is not permitted during screening to meet eligibility
             criteria and within 14 days of initiation of therapy

          -  Platelet count ≥ 70,000 cells/dL (70 x 10^9/L) Platelet transfusion is not permitted
             during screening to meet eligibility criteria and within 14 days of initiation of
             therapy

          -  Hemoglobin ≥ 8.0 g/dl ( red blood cell (RBC) transfusions are permitted during the
             screening period)

          -  Total Bilirubin ≤ 1.5 X upper limit of normal (ULN) ; Aspartate transaminase (AST, or
             SGOT) and alanine transaminase (ALT, or SGPT) ≤ 2.5x ULN Estimated creatinine
             clearance by Cockcroft-Gault formula ≥ 50 mL/min

        Exclusion Criteria:

          -  Diagnosed or treated for another malignancy within 3 years prior to enrollment, with
             the exception of complete resection of basal cell carcinoma or squamous cell carcinoma
             of the skin, an in situ malignancy, or low risk prostate cancer after curative
             therapy.

          -  Received any investigational drug within 14 days or 5 half-lives of the
             investigational drug, whichever is longer.

          -  Prior anti-cancer therapy within 14 days.

          -  Patient has any Grade 3 or &gt; unresolved peripheral neuropathy from previous treatment.

          -  Patient is human immunodeficiency virus (HIV) positive,.

          -  Patient is Hepatitis B Surface antigen-positive or HBV-DNA copies &gt; 10^3/ml

          -  Patient has active hepatitis C infection.

          -  Hypersensitivity to any of the required concomitant drugs or supportive treatments,
             including hypersensitivity to antiviral drugs

          -  Known history of allergy to 2 or &gt; drugs or any component of regimen

          -  Any clinically significant, uncontrolled medical conditions that, in the treating
             Investigator's opinion, would impose excessive risk to the patient or may interfere
             with compliance or interpretation of the study results. Uncontrolled intercurrent
             illness may include, but is not limited to, ongoing or active infection, symptomatic
             congestive heart failure, unstable angina pectoris, clinically significant cardiac
             arrhythmia, or psychiatric illness/social situations as determined by treating
             investigator that would limit compliance with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Liu, MD ,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Wei, MD</last_name>
    <phone>00862164041990</phone>
    <phone_ext>2925</phone_ext>
    <email>wei.zheng@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>July 21, 2018</last_update_submitted>
  <last_update_submitted_qc>July 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Peng Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

